{"ticker": {"uuid": "e1a7e980-fb87-4a6d-ace4-a819c60c2eba", "symbol": "VANI", "name": "Vivani Medical Inc.", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Vivani Medical Insider Bought Shares Worth $999,999, According to a Recent SEC Filing", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/vivani-medical-insider-bought-shares-131844886.html", "source_name": "MT Newswires", "published_at": "2026-07-16T13:18:44+00:00", "published_display": "16 Jul 2026 13:18", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Vivani Medical Inc For: 16 July By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxOSW5QU2dST3NieUttaDNCdFlDVk90SHFoNUI4d1FtOHBHbHB3RlFybzVpV1Z1Ykg5Tm80dFBGQ0o1eDdSMkpRRmhKQ096b3Jya3U2OEFsNy1YRUNIU08yZHVYRDd2azVoYUNsemhsd0M3LVhPem9qaldQVmEtWkZSdFNaUjVRcGtBTV9vblZLTTAwZ05Rblh4RXRVdDBReFU?oc=5", "source_name": "Investing.com Canada", "published_at": "2026-07-16T13:16:01+00:00", "published_display": "16 Jul 2026 13:16", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vivani Medical director Gregg Williams buys $1m in stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxPVUNYdzh0a1hrXzlodGJDLUVXNmRRU1plWGc2RURkaGltMWtHSmJ4RUdDWTBMd3VRLW43Y1RmUEc2QS1NLW9uNlBDODZ0SjFMYkY2ZW5DUm9BNVgtNE1uMzBpLVJoUFZGWFhUanJEUUtyTUozWnFwR1QwRTZjNldZMmlVUlBhTEQxenlRSjZFSEZ1UUpIbFZoWFd2Q0tQNk9iNHFDc0RSRFlYQWp4VWNHQlZxdjhZdFE4bUVCMg?oc=5", "source_name": "Investing.com", "published_at": "2026-07-16T13:04:38+00:00", "published_display": "16 Jul 2026 13:04", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vivani Medical at emerging growth conference: implant push gains traction By Investing.com", "summary": "Vivani Medical (VANI) presented its implant-based drug delivery platform at the Emerging Growth Conference, highlighting new interest from Novo Nordisk for evaluating its semaglutide implants and progress towards its first semaglutide study. The company plans to begin its SLIM-1 ", "url": "https://m.za.investing.com/news/transcripts/vivani-medical-at-emerging-growth-conference-implant-push-gains-traction-93CH-4371202?ampMode=1", "source_name": "Investing.com South Africa", "published_at": "2026-07-16T04:11:51", "published_display": "16 Jul 2026 04:11", "sentiment": "positive", "sentiment_pct": 92, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vivani Medical (VANI) Emerging Growth Conference Summary", "summary": "Vivani Medical presented at the Emerging Growth Conference, highlighting a new agreement with Novo Nordisk for its semaglutide implant and preparing to initiate the SLIM-1 clinical trial in August. The implant offers infrequent administration, steady drug release, and addresses a", "url": "https://quartr.com/events/vivani-medical-inc-vani-emerging-growth-conference_FeVShtZT", "source_name": "Quartr", "published_at": "2026-07-16T04:11:51", "published_display": "16 Jul 2026 04:11", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vivani Medical Eyes August Human Trial for Semaglutide Implant After Novo Nordisk Deal", "summary": "", "url": "https://finance.yahoo.com/m/7467b79f-7740-398e-a152-56b22e4aaf9f/vivani-medical-eyes-august.html", "source_name": "MarketBeat", "published_at": "2026-07-15T23:02:22+00:00", "published_display": "15 Jul 2026 23:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vivani Medical to Present at the Emerging Growth Conference on July 15, 2026", "summary": "Vivani Medical, Inc. announced that it will present at the Emerging Growth Conference on July 15, 2026, at 4:10 p.m. Eastern Time. CEO Adam Mendelsohn will provide a company update on their miniature, GLP-1 drug implants designed for once- or twice-yearly administration for metab", "url": "https://www.globenewswire.com/de/news-release/2026/07/14/3327241/0/en/Vivani-Medical-to-Present-at-the-Emerging-Growth-Conference-on-July-15-2026.html", "source_name": "GlobeNewswire", "published_at": "2026-07-15T00:14:59", "published_display": "15 Jul 2026 00:14", "sentiment": "positive", "sentiment_pct": 63, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vivani Medical to present its GLP-1 drug implant technology at Emerging Growth Conference July 15, 2026", "summary": "Vivani Medical, a biopharmaceutical company, will present its miniature GLP-1 drug implants for metabolic diseases at the Emerging Growth Conference on July 15, 2026. These implants aim to improve medication adherence by providing once- or twice-yearly drug delivery, addressing c", "url": "https://pluang.com/en/news-feed/vivani-medical-akan-mempresentasikan-di-konferensi-emerging-growth-juli-2026", "source_name": "Pluang", "published_at": "2026-07-14T20:10:11", "published_display": "14 Jul 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vivani CEO to give company update in July 15 webcast", "summary": "Vivani Medical (NASDAQ: VANI) announced that its CEO, Adam Mendelsohn, Ph.D., will present a company update at the Emerging Growth Conference on July 15, 2026, at 4:10 p.m. Eastern Time. The presentation will include an interactive session with live Q&A, and an archived webcast w", "url": "https://www.stocktitan.net/news/VANI/vivani-medical-to-present-at-the-emerging-growth-conference-on-july-j7a53z0hdzd1.html", "source_name": "Stock Titan", "published_at": "2026-07-14T20:10:11", "published_display": "14 Jul 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A tiny GLP-1 implant is the latest bet to help patients maintain their weight loss", "summary": "Vivani Medical is developing a tiny GLP-1 implant designed to help patients maintain weight loss long-term, addressing issues like injection fatigue and treatment adherence common with existing GLP-1 drugs. The implant, containing semaglutide, is intended as a maintenance therapy", "url": "https://www.cnbc.com/2026/07/11/glp-1-implant-from-vivani-medical-aims-to-help-patients-stay-on-treatment.html", "source_name": "CNBC", "published_at": "2026-07-12T11:11:46", "published_display": "12 Jul 2026 11:11", "sentiment": "positive", "sentiment_pct": 63, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright reiterates Vivani Medical stock rating on Novo deal", "summary": "H.C. Wainwright has reiterated a Buy rating and a $3.50 price target for Vivani Medical (NASDAQ:VANI) following the company's agreement with Novo Nordisk to evaluate NPM-139, Vivani's semaglutide drug implant for chronic weight management. This agreement is seen as external valid", "url": "https://www.investing.com/news/analyst-ratings/hc-wainwright-reiterates-vivani-medical-stock-rating-on-novo-deal-93CH-4786014", "source_name": "Investing.com", "published_at": "2026-07-10T12:39:30", "published_display": "10 Jul 2026 12:39", "sentiment": "positive", "sentiment_pct": 70, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright reiterates Vivani Medical stock rating on Novo deal By Investing.com", "summary": "H.C. Wainwright has reiterated its Buy rating and a $3.50 price target for Vivani Medical (NASDAQ:VANI) following the company's agreement with Novo Nordisk. Vivani Medical's stock surged 24% over the past week after announcing a deal for Novo Nordisk to evaluate NPM-139, Vivani\u2019s", "url": "https://au.investing.com/news/stock-market-news/hc-wainwright-reiterates-vivani-medical-stock-rating-on-novo-deal-93CH-4527692", "source_name": "Investing.com Australia", "published_at": "2026-07-10T12:10:31", "published_display": "10 Jul 2026 12:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analysts Set Expectations for Vivani Medical Q1 Earnings", "summary": "HC Wainwright initiated Q1 2027 earnings estimates for Vivani Medical (NASDAQ:VANI) at a loss of $0.07 per share, maintaining a Buy rating and a $3.50 price target. Despite this, the broader analyst view is more cautious with an average \"Hold\" rating and a $3.75 price target. The", "url": "https://www.marketbeat.com/instant-alerts/analysts-set-expectations-for-vivani-medical-q1-earnings-2026-07-10/", "source_name": "MarketBeat", "published_at": "2026-07-10T12:10:31", "published_display": "10 Jul 2026 12:10", "sentiment": "positive", "sentiment_pct": 61, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Maxim Group Maintains Vivani Medical(VANI.US) With Buy Rating, Maintains Target Price $4", "summary": "Maxim Group has reiterated its Buy rating for Vivani Medical (VANI.US) and maintained its target price at $4. This indicates continued confidence from the firm in the company's performance and future prospects.", "url": "https://www.moomoo.com/news/post/72717105/maxim-group-maintains-vivani-medical-vanius-with-buy-rating-maintains", "source_name": "Moomoo", "published_at": "2026-07-10T10:39:30", "published_display": "10 Jul 2026 10:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Novo Nordisk (CPSE:NOVO B) Could Be 13% Overvalued Following Its Vivani Deal", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/novo-nordisk-cpse-novo-b-161205528.html", "source_name": "Simply Wall St.", "published_at": "2026-07-09T16:12:05+00:00", "published_display": "09 Jul 2026 16:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vivani Medical (VANI) Receives a Buy from Lake Street", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1AFBVV95cUxOM2FPc3czV3VTWmdwak1pc0RDVEQxbWJrUE1TUlU4MEpyQzlLWlJzZFVBd1VMUDJ5ZWJIRVZSaUNTcnBJN2VXbTVZSWRZWjFnX2xCeUtPRGJkaHhlY2ZHTm1zYjRqOW1HNHVtdWZLWU82RzBsS21mcW91b1Eya2tINndHVzJQMFdLeGY3N3BOcFl4WWMzaXFzU21HZGZkODk3VjNkRWticWVwQlVrT3JCZW1TRkwzd3VUZGxDMkQ2YmNVT2R5ZUJtWmNyOW12c2ZkRDV3eA?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-07-08T13:06:00+00:00", "published_display": "08 Jul 2026 13:06", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vivani Advances GLP-1 Implant Program With Novo Nordisk", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2gFBVV95cUxQQjE1cktuQ1Vvcl95cUc5VzZDdGxyamd5Qm5NM0pxUkI5U1MyWjYzWnhaZVpIUUxtT25wQ0ZCU1BvN18zSGZtME5fSE4xYnhod2RFcFExVmw2V1FZYXdRc090eEtKWUp1SWYza3hhaGZQT2xoZmJsbGFQQkxXN2RjWVItTkkxWFpLVE8xQnNzcFNtWWFhY3dpWXJQcmwxSFJpY3VpWFFkR0ZoQUppdFA2UWRKcWRndW1qdVIyTnNUTk85cGl5c3JuQkdjT1VGUjAzNWhOazlpV1AxQQ?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-07-08T12:34:00+00:00", "published_display": "08 Jul 2026 12:34", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Novo Nordisk signs pact with Vivani for long-lasting semaglutide implant", "summary": "", "url": "https://finance.yahoo.com/m/1b4a9ea6-034d-3933-8cbb-34d4e0ca83d5/novo-nordisk-signs-pact-with.html", "source_name": "Pharmaceutical Technology", "published_at": "2026-07-08T11:11:06+00:00", "published_display": "08 Jul 2026 11:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vivani Medical Enters into Agreement with Novo Nordisk to Evaluate NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight Management", "summary": "Vivani Medical has signed an agreement with Novo Nordisk to evaluate NPM-139, Vivani\u2019s ultra long-acting semaglutide implant for chronic weight management. This confirms Novo Nordisk's interest in assessing the NanoPortal\u2122 technology and its semaglutide application. Vivani plans ", "url": "https://www.barchart.com/story/news/3159576/vivani-medical-enters-into-agreement-with-novo-nordisk-to-evaluate-npm-139-a-miniature-ultra-long-acting-semaglutide-implant-for-chronic-weight-management", "source_name": "Barchart.com", "published_at": "2026-07-08T10:39:30", "published_display": "08 Jul 2026 10:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lake Street Maintains Vivani Medical(VANI.US) With Buy Rating, Maintains Target Price $4", "summary": "Lake Street maintained its Buy rating on Vivani Medical (VANI.US) and kept its target price at $4. This indicates continued confidence in the company's prospects from the analyst firm.", "url": "https://www.moomoo.com/news/post/72590558/lake-street-maintains-vivani-medical-vanius-with-buy-rating-maintains", "source_name": "Moomoo", "published_at": "2026-07-07T22:10:31", "published_display": "07 Jul 2026 22:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Novo Nordisk (CPSE:NOVO B) Teams Up With Vivani To Test A Semaglutide Implant", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/novo-nordisk-cpse-novo-b-191804898.html", "source_name": "Simply Wall St.", "published_at": "2026-07-07T19:18:04+00:00", "published_display": "07 Jul 2026 19:18", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vivani Flat on Hookup with Novo", "summary": "Vivani Medical, Inc. announced a new agreement allowing Novo Nordisk to evaluate its semaglutide drug implant, NPM-139, for chronic weight management. Vivani expects to start a Phase 1 study for NPM-139 in mid-2026, comparing it to Wegovy\u00ae injections. This collaboration highlight", "url": "https://www.baystreet.ca/amp/articles/stockstowatch.aspx?articleid=122123", "source_name": "Baystreet.ca", "published_at": "2026-07-07T16:42:11", "published_display": "07 Jul 2026 16:42", "sentiment": "positive", "sentiment_pct": 66, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vivani Medical Says Novo Nordisk to Evaluate Semaglutide Implant for Weight Management", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/vivani-medical-says-novo-nordisk-115918611.html", "source_name": "MT Newswires", "published_at": "2026-07-07T11:59:18+00:00", "published_display": "07 Jul 2026 11:59", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Novo Nordisk will evaluate Vivani\u2019s semaglutide implant for weight loss", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxPSzJYbG5PSkx2M0VlNDA1SG1oQ3ExX3FTRndTUkhXX1g3YTJuQzN2cGZsVjR3TEJLV0VGNk5yZFRZb255RXpTbVF1cmxRd09ET2JaMXBEdHQ1ZElHSE00LUJDUEVJNENMOGFXbkItaTBDZkRtTlBZMG1CYVFvQ2dHZGo1SFNhY1FVQVZGdTAyN0Q0SGd5SWFqQXB6dU5vVjJZbU9sX0tZejdLdE5lSTZ6M1pibGxxOFlPdy1tcDhn?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-07T11:35:00+00:00", "published_display": "07 Jul 2026 11:35", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ClearOne (Nasdaq: CLRO) sets Cortigent merger, Vivani majority stake and $10\u201315M raise", "summary": "ClearOne, Inc. has announced a definitive merger agreement to acquire Cortigent, Inc., a wholly-owned subsidiary of Vivani Medical, Inc. Vivani will receive 12.5 million ClearOne shares, subsequently owning 59.4%\u201367.5% of the combined company, which will be renamed Cortigent Hold", "url": "https://www.stocktitan.net/sec-filings/CLRO/8-k-clearone-inc-reports-material-event-3231d958d02f.html", "source_name": "Stock Titan", "published_at": "2026-07-06T20:31:18", "published_display": "06 Jul 2026 20:31", "sentiment": "positive", "sentiment_pct": 64, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "We're Keeping An Eye On Vivani Medical's (NASDAQ:VANI) Cash Burn Rate", "summary": "Vivani Medical (NASDAQ:VANI) has a critical cash burn situation, with a cash runway of only about 9 months as of March 2026. The company, which is in an early stage without revenue, increased its cash burn by 22% over the last year. Shareholders face potential costly dilution if ", "url": "https://www.sahmcapital.com/news/content/were-keeping-an-eye-on-vivani-medicals-nasdaqvani-cash-burn-rate-2026-07-03", "source_name": "Sahm", "published_at": "2026-07-03T21:09:55", "published_display": "03 Jul 2026 21:09", "sentiment": "negative", "sentiment_pct": 24, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vivani strikes reverse-merger agreement with ClearOne for BCI business", "summary": "Vivani Medical has agreed to merge its neurotech subsidiary, Cortigent, with ClearOne to form a new publicly traded entity, Cortigent Holdings (CRGT), which will focus on brain-computer interface (BCI) technology. Under the agreement, Vivani will hold a majority stake in the new ", "url": "https://finance.yahoo.com/healthcare/articles/vivani-strikes-reverse-merger-agreement-114021364.html", "source_name": "Market source", "published_at": "2026-07-03T11:40:00", "published_display": "03 Jul 2026 11:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Press Release: ClearOne Announces Entry Into Merger Agreement With Cortigent, Inc., a Wholly-Owned Subsidiary of Vivani Medical", "summary": "ClearOne, Inc. has announced a definitive merger agreement with Cortigent, Inc., a wholly-owned subsidiary of Vivani Medical. This strategic transaction will result in Cortigent becoming a public company and is fully supported by Vivani Medical and Cortigent's existing investors.", "url": "https://www.moomoo.com/news/post/72398173/press-release-clearone-announces-entry-into-merger-agreement-with-cortigent", "source_name": "Moomoo", "published_at": "2026-07-02T20:10:13", "published_display": "02 Jul 2026 20:10", "sentiment": "positive", "sentiment_pct": 66, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ClearOne stock surges 50% on Vivani merger deal By Investing.com", "summary": "ClearOne Inc. shares surged over 52% after announcing a merger agreement with Cortigent Inc., a subsidiary of Vivani Medical Inc. Vivani will receive 12.5 million shares of ClearOne common stock, resulting in Vivani owning 59.4% to 67.5% of the combined company, which will be ren", "url": "https://m.za.investing.com/news/stock-market-news/clearone-stock-surges-50-on-vivani-merger-deal-93CH-4354254?ampMode=1", "source_name": "Investing.com South Africa", "published_at": "2026-07-02T15:41:14", "published_display": "02 Jul 2026 15:41", "sentiment": "positive", "sentiment_pct": 72, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vivani to sell neurotech subsidiary Cortigent to ClearOne", "summary": "Vivani Medical announced a definitive agreement to sell its neurotech subsidiary, Cortigent, to ClearOne. The transaction will result in ClearOne being renamed \"Cortigent Holdings, Inc.\" and trading under the Nasdaq ticker \"CRGT,\" with Vivani retaining a majority stake. This move", "url": "https://www.massdevice.com/vivani-sell-neurotech-subsidiary-cortigent-clearone/", "source_name": "MassDevice", "published_at": "2026-07-02T15:41:13", "published_display": "02 Jul 2026 15:41", "sentiment": "positive", "sentiment_pct": 72, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ClearOne Announces Entry into Merger Agreement with Cortigent, Inc., a Wholly-Owned Subsidiary of Vivani Medical", "summary": "ClearOne, Inc. has entered into a definitive merger agreement with Cortigent, Inc., a wholly-owned subsidiary of Vivani Medical. As part of the transaction, Cortigent will become a wholly-owned subsidiary of ClearOne, and ClearOne will conduct a financing round to raise $10 milli", "url": "https://www.businesswire.com/news/home/20260702293602/en/ClearOne-Announces-Entry-into-Merger-Agreement-with-Cortigent-Inc.-a-Wholly-Owned-Subsidiary-of-Vivani-Medical", "source_name": "Business Wire", "published_at": "2026-07-02T11:41:13", "published_display": "02 Jul 2026 11:41", "sentiment": "positive", "sentiment_pct": 66, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vivani Announces Entry into Merger Agreement Between Wholly Owned Subsidiary Cortigent, Inc. and Nasdaq-listed ClearOne, Inc.", "summary": "Vivani Medical, Inc. announced a definitive merger agreement between its wholly-owned subsidiary Cortigent, Inc. and Nasdaq-listed ClearOne", "url": "https://www.globenewswire.com/news-release/2026/07/02/3321264/0/en/vivani-announces-entry-into-merger-agreement-between-wholly-owned-subsidiary-cortigent-inc-and-nasdaq-listed-clearone-inc.html", "source_name": "GlobeNewswire", "published_at": "2026-07-02T11:41:13", "published_display": "02 Jul 2026 11:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Vivani Medical, Inc. \u2013 NASDAQ:VANI", "summary": "This article provides a financial overview of Vivani Medical, Inc. (NASDAQ: VANI), specifically focusing on its forward price-to-earnings ratio. It indicates that the market was closed at the time of the report and there were no trades. The article is primarily a data page from T", "url": "https://www.tradingview.com/symbols/NASDAQ-VANI/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-01T07:39:41", "published_display": "01 Jul 2026 07:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vivani Medical (NASDAQ: VANI) wins HREC nod for SLIM-1 semaglutide implant trial", "summary": "Vivani Medical has received approval from Bellberry, an Australian human research ethics committee, to begin its SLIM-1 Phase 1 clinical trial for NPM-139, a semaglutide implant aimed at obesity and chronic weight management. The trial will assess the safety, tolerability, and ph", "url": "https://www.stocktitan.net/sec-filings/VANI/8-k-vivani-medical-inc-reports-material-event-5764a99801a8.html", "source_name": "Stock Titan", "published_at": "2026-06-30T20:10:12", "published_display": "30 Jun 2026 20:10", "sentiment": "positive", "sentiment_pct": 65, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Vivani Medical Inc. \u2013 DUS:U5P", "summary": "The article focuses solely on the enterprise value to EBIT forward for Vivani Medical Inc. (DUS:U5P). It provides no specific financial figures but presents the topic as a data point for the company listed on the Dusseldorf Stock Exchange. The content is primarily a header and na", "url": "https://www.tradingview.com/symbols/DUS-U5P/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T18:09:43", "published_display": "27 Jun 2026 18:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vivani Medical Announces Appointment of August J. Moretti to Board of Directors and Retirement of Dr. Dean Baker", "summary": "Vivani Medical, Inc. (NASDAQ: VANI) has announced the appointment of August Moretti to its board of directors, where he will chair the Audit Committee and serve on the Compensation Committee. Concurrently, Dr. Dean Baker has retired from the board after a distinguished tenure. Th", "url": "https://www.globenewswire.com/news-release/2026/06/26/3318161/0/en/vivani-medical-announces-appointment-of-august-j-moretti-to-board-of-directors-and-retirement-of-dr-dean-baker.html", "source_name": "GlobeNewswire", "published_at": "2026-06-27T07:09:35", "published_display": "27 Jun 2026 07:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vivani wins approval to start obesity implant trial in Australia", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxNcmwwLXBkLUczMXNCLUtzVVU2NDdiUW5hMDNPQ2NGYlZPZEVSRVo5UVBvTU5pTnRPMDNtazFjb0VfcnZHU1FsSVpQeWFTVWpqZzZRZ0YwZDhtUzBKZzM1bDRPU2VHbUFmb2JJVUphblpCYXM2cEZnUWVMWDFrTXpLNUlPOVdWNG4xYkQxaHI3cS1pWmR6UFR2R2syNGlKaWVCX056VDNPUHU0N1JrVW8tQjk5Znc4MGl5QWx2ZA?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[Form 4] Vivani Medical, Inc. Insider Trading Activity", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxNZHRrdTJnOFhpa3pxc1FVWnBuWG1BZlo1bGt2aHQtUGl4Y2d0SlVna2RKbDRfTFM1dGFlZVhPTXNrNkt6Uk9hX250cGx0b0ZvUXYtdWJIeFQ0dW94T0k5Y0RHMnktckU0a3c0b2pPNXgzTlgyYl9LSnNkOU1iYXVXYm1XajRzRV8wdWlfMkJjNWZ2QWJnbXBIUG0tTzBpR2J4ZXl4LUl5dm9BTUlOQzlzU0dB?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lake Street initiates Vivani Medical stock with buy on implant tech", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxQTEt1aDRVbDlKQ3hlNGcxcHNUYzY3eFFyQlg0cEZ6Y0JkeXVxQTFWR3pjNWtNMWV1XzJWQ3lyQXM0YVRHYlIxUVNMTkxzLWJVMVRoV2FtZ0h2eFlKcjVXNmhnNEpaNUVkQTcyaV82QVBlVEp0QzhzbnpxX3l0VUhpU1NMeVJVYTJYaUswd1RIY1RaakhtZjdNV1UzVjlmZ1QyN0dMcm9zRVUxVWxlV2tXRUYyRThlTDJ4Q2RhZFY3UEJUUEJyc2c?oc=5", "source_name": "Investing.com", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's Why We're Watching Vivani Medical's (NASDAQ:VANI) Cash Burn Situation", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxON0VkRF81QnJWNmpVRjhacHFYSlRpckRFVFlXa0hDTFlLQkx3MHlCY0lwd0tRZmpLaG5hZXVmVXVYMU1xNzIwNDB1VVY5Z2tLaG9hSFdLUXpPNDFMZHREWHgxRzYzV3Z3NUVIbmVxWnFXXy0tRGNGb3c0Z05aRlg3T0o2V2UySy1NVzBRSDdNTHNtZWd4T3prSUQtSQ?oc=5", "source_name": "Market source", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxOWWM3V1pmZzdlY1llRTljQmNLQ2UwdDdQaFVEcng2WVdrNE9qNzRrNVpBVlJNMGltQUhBUG1qellCVHNiM09fUkFHRW1kMEpvazJoLU11N3c4YnlWUXpmVl82aWNKeTA4U1RwSHNNSVd4d0lwWHRJclQ2TGNHWUpBQTgzbTBMVk05VGxYN0RwcmpTYklOQUFSWDhsSHZlQVpndmlPRGNvTmRmeHNILWg4ZE5jMjRoN01XNENiaVU2UDUyOWJfYUZCTm5URmtwTHJsTjJYNHo3RkxsQjBSMnBmdVZVWkFwN2PSAewBQVVfeXFMT3htM016bEt0TTdyOXE2amppMGpubTNfOFU4cGpxd2dFZkJDTjR3c0ZqOHpHYWZoamNLdmkxVmNYNklxTEM4NTU0bDZwUTZ1SW5Jc1c4NmRJN3lKQUVqUUNYYWptd2ZYNE9TeEhMRzFvbEt0bjk1TVhyVG44UnJnNDllTlFsalJVUTZwcEEzWXljbzdaQXdWWDlHQW56bGxqeG90UlFmaFFLekJlUlNIOVE4SGNHcE9pOW1KSllleVdwNERiaVl2NmxtNTNyaUtnSFY1VHUzcDJsWE9xb3R1ajZ2RGhkXzJzTldMOVA?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Vivani Medical (VANI) Upgraded to Buy: What Does It Mean for the Stock?", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPanplVnRHNFJlZzFCcmRsOGJrb2xUOG1HMkJnUEJFcjExMlRyYmU3Znh6NkctbjZaUVBkeHZvb3Q1dkw0RWlHZWpiRk1CYTl2NWdQcHJZUGVCZkp0UnVzNi1NR0oxSjA0elBULXlSaFF1VjFmQkxSV0Vmcy1tV0xSbVVMdG5EZ3kxYXIteDdMSndpZFNfQ1JkOW8yS2M5dw?oc=5", "source_name": "Market source", "published_at": "2026-04-03T07:00:00+00:00", "published_display": "03 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 84, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Should I buy Vivani Medical, Inc. (VANI)", "summary": "", "url": "https://news.google.com/rss/articles/CBMibEFVX3lxTE1ET1FjWFM3LVFQSmxPTkRJM05FRl9QSmxXbHhFOHZ6czlNVVZSQ3RmMzhtWUVrSVFSQzhGc0FVUW04LWR5QUVLSG5DaEhHVG5oM19meFBQUXZkWTlsYnFsS3YxTmtVYVNFU3ljQw?oc=5", "source_name": "Zacks Investment Research", "published_at": "2026-04-03T07:00:00+00:00", "published_display": "03 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Vivani medical director Williams buys shares worth $1.68 million", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxPQzhBUFBPNHRpNWJ2cEdZWEdDbkhwamNXN0RKazZONE1GeFhRMmlRTm1HV3NLS1h2Zmc5TUFzOHNWVk5UUUhPQ1VqWkpBMXpzU3lfekxTREpmbjhPM01JaWdQd0VheU9KTWpCd2lPZ2ZiUGtnaEt4QmlqWlJ4cXRxWXQ5bjBaRDJIQ2pROWlUZUx0Z29KRzZJQlVWR0pRd3VrS091RUo3eTNxeWhxY1ZCTnczQlRFQ3d4Y0JDUkx1eWNfYkR6Zmc?oc=5", "source_name": "Investing.com", "published_at": "2026-03-16T07:00:00+00:00", "published_display": "16 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vivani Medical, Inc. Announces Closing of Common Stock Offering", "summary": "", "url": "https://news.google.com/rss/articles/CBMiigFBVV95cUxOc0NvTFZCcXNxOUZ3MDBKUjExMENMREthcW5DQzl3aDc1blA2Rlp0cnh4QzZHa3VtQ3hjbHZobVVFOXJsaUxRcUhoR3pLQjNXT296VE9XVFdveTB2a3laVDg2V2Jxc3RhbUdzdTRJZWFzM19US1FkaUJ6WndRREFDZWV5Y0JGd3Y3YVE?oc=5", "source_name": "Market source", "published_at": "2026-01-27T08:00:00+00:00", "published_display": "27 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vivani Medical, Inc. (NASDAQ:VANI) insiders have had a fantastic week as stock increased 17%, and they haven't stopped buying", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-23T08:00:00+00:00", "published_display": "23 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insiders hold 43% of Vivani Medical, Inc. (NASDAQ:VANI), and they've been buying recently", "summary": "", "url": "https://news.google.com/rss/articles/CBMigwFBVV95cUxPS0p6V2RIWEpvb2VOUFNEa3dNLXZsTVU2dW13WDllOXpnaUhaajBUWDJyWExBUGx5WFc4SkxKUU9wRlFxWThPdTlKQS1zcHh6SlAtVlQyUzlkTDNvNW9COU9xcDNtbnNzNzNzcUJIQU9IejNWTGdrV1ItSW5PcVJ5OGpDYw?oc=5", "source_name": "Market source", "published_at": "2025-12-05T08:00:00+00:00", "published_display": "05 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vivani Medical (VANI) Stock Price, News & Analysis $VANI", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE5HTnNhN3MydTAxYTVWdzRjWWNRblhNUXNRakpxRVRPSVlSalJUWXVjQlIybkcyMVYwTXUwUEJIcUNFQ3Vzd1BrR09XZDN3VS1pU2ZOUm10ei1oUQ?oc=5", "source_name": "MarketBeat", "published_at": "2022-09-06T12:39:02+00:00", "published_display": "06 Sep 2022 12:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Vivani Medical Insider Bought Shares Worth $999,999, According to a Recent SEC Filing", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/vivani-medical-insider-bought-shares-131844886.html", "source_name": "MT Newswires", "published_at": "2026-07-16T13:18:44+00:00", "published_display": "16 Jul 2026 13:18", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Vivani Medical Inc For: 16 July By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxOSW5QU2dST3NieUttaDNCdFlDVk90SHFoNUI4d1FtOHBHbHB3RlFybzVpV1Z1Ykg5Tm80dFBGQ0o1eDdSMkpRRmhKQ096b3Jya3U2OEFsNy1YRUNIU08yZHVYRDd2azVoYUNsemhsd0M3LVhPem9qaldQVmEtWkZSdFNaUjVRcGtBTV9vblZLTTAwZ05Rblh4RXRVdDBReFU?oc=5", "source_name": "Investing.com Canada", "published_at": "2026-07-16T13:16:01+00:00", "published_display": "16 Jul 2026 13:16", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vivani Medical director Gregg Williams buys $1m in stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxPVUNYdzh0a1hrXzlodGJDLUVXNmRRU1plWGc2RURkaGltMWtHSmJ4RUdDWTBMd3VRLW43Y1RmUEc2QS1NLW9uNlBDODZ0SjFMYkY2ZW5DUm9BNVgtNE1uMzBpLVJoUFZGWFhUanJEUUtyTUozWnFwR1QwRTZjNldZMmlVUlBhTEQxenlRSjZFSEZ1UUpIbFZoWFd2Q0tQNk9iNHFDc0RSRFlYQWp4VWNHQlZxdjhZdFE4bUVCMg?oc=5", "source_name": "Investing.com", "published_at": "2026-07-16T13:04:38+00:00", "published_display": "16 Jul 2026 13:04", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vivani Medical at emerging growth conference: implant push gains traction By Investing.com", "summary": "Vivani Medical (VANI) presented its implant-based drug delivery platform at the Emerging Growth Conference, highlighting new interest from Novo Nordisk for evaluating its semaglutide implants and progress towards its first semaglutide study. The company plans to begin its SLIM-1 ", "url": "https://m.za.investing.com/news/transcripts/vivani-medical-at-emerging-growth-conference-implant-push-gains-traction-93CH-4371202?ampMode=1", "source_name": "Investing.com South Africa", "published_at": "2026-07-16T04:11:51", "published_display": "16 Jul 2026 04:11", "sentiment": "positive", "sentiment_pct": 92, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vivani Medical (VANI) Emerging Growth Conference Summary", "summary": "Vivani Medical presented at the Emerging Growth Conference, highlighting a new agreement with Novo Nordisk for its semaglutide implant and preparing to initiate the SLIM-1 clinical trial in August. The implant offers infrequent administration, steady drug release, and addresses a", "url": "https://quartr.com/events/vivani-medical-inc-vani-emerging-growth-conference_FeVShtZT", "source_name": "Quartr", "published_at": "2026-07-16T04:11:51", "published_display": "16 Jul 2026 04:11", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vivani Medical Eyes August Human Trial for Semaglutide Implant After Novo Nordisk Deal", "summary": "", "url": "https://finance.yahoo.com/m/7467b79f-7740-398e-a152-56b22e4aaf9f/vivani-medical-eyes-august.html", "source_name": "MarketBeat", "published_at": "2026-07-15T23:02:22+00:00", "published_display": "15 Jul 2026 23:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vivani Medical to Present at the Emerging Growth Conference on July 15, 2026", "summary": "Vivani Medical, Inc. announced that it will present at the Emerging Growth Conference on July 15, 2026, at 4:10 p.m. Eastern Time. CEO Adam Mendelsohn will provide a company update on their miniature, GLP-1 drug implants designed for once- or twice-yearly administration for metab", "url": "https://www.globenewswire.com/de/news-release/2026/07/14/3327241/0/en/Vivani-Medical-to-Present-at-the-Emerging-Growth-Conference-on-July-15-2026.html", "source_name": "GlobeNewswire", "published_at": "2026-07-15T00:14:59", "published_display": "15 Jul 2026 00:14", "sentiment": "positive", "sentiment_pct": 63, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vivani Medical to present its GLP-1 drug implant technology at Emerging Growth Conference July 15, 2026", "summary": "Vivani Medical, a biopharmaceutical company, will present its miniature GLP-1 drug implants for metabolic diseases at the Emerging Growth Conference on July 15, 2026. These implants aim to improve medication adherence by providing once- or twice-yearly drug delivery, addressing c", "url": "https://pluang.com/en/news-feed/vivani-medical-akan-mempresentasikan-di-konferensi-emerging-growth-juli-2026", "source_name": "Pluang", "published_at": "2026-07-14T20:10:11", "published_display": "14 Jul 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vivani CEO to give company update in July 15 webcast", "summary": "Vivani Medical (NASDAQ: VANI) announced that its CEO, Adam Mendelsohn, Ph.D., will present a company update at the Emerging Growth Conference on July 15, 2026, at 4:10 p.m. Eastern Time. The presentation will include an interactive session with live Q&A, and an archived webcast w", "url": "https://www.stocktitan.net/news/VANI/vivani-medical-to-present-at-the-emerging-growth-conference-on-july-j7a53z0hdzd1.html", "source_name": "Stock Titan", "published_at": "2026-07-14T20:10:11", "published_display": "14 Jul 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A tiny GLP-1 implant is the latest bet to help patients maintain their weight loss", "summary": "Vivani Medical is developing a tiny GLP-1 implant designed to help patients maintain weight loss long-term, addressing issues like injection fatigue and treatment adherence common with existing GLP-1 drugs. The implant, containing semaglutide, is intended as a maintenance therapy", "url": "https://www.cnbc.com/2026/07/11/glp-1-implant-from-vivani-medical-aims-to-help-patients-stay-on-treatment.html", "source_name": "CNBC", "published_at": "2026-07-12T11:11:46", "published_display": "12 Jul 2026 11:11", "sentiment": "positive", "sentiment_pct": 63, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright reiterates Vivani Medical stock rating on Novo deal", "summary": "H.C. Wainwright has reiterated a Buy rating and a $3.50 price target for Vivani Medical (NASDAQ:VANI) following the company's agreement with Novo Nordisk to evaluate NPM-139, Vivani's semaglutide drug implant for chronic weight management. This agreement is seen as external valid", "url": "https://www.investing.com/news/analyst-ratings/hc-wainwright-reiterates-vivani-medical-stock-rating-on-novo-deal-93CH-4786014", "source_name": "Investing.com", "published_at": "2026-07-10T12:39:30", "published_display": "10 Jul 2026 12:39", "sentiment": "positive", "sentiment_pct": 70, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright reiterates Vivani Medical stock rating on Novo deal By Investing.com", "summary": "H.C. Wainwright has reiterated its Buy rating and a $3.50 price target for Vivani Medical (NASDAQ:VANI) following the company's agreement with Novo Nordisk. Vivani Medical's stock surged 24% over the past week after announcing a deal for Novo Nordisk to evaluate NPM-139, Vivani\u2019s", "url": "https://au.investing.com/news/stock-market-news/hc-wainwright-reiterates-vivani-medical-stock-rating-on-novo-deal-93CH-4527692", "source_name": "Investing.com Australia", "published_at": "2026-07-10T12:10:31", "published_display": "10 Jul 2026 12:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analysts Set Expectations for Vivani Medical Q1 Earnings", "summary": "HC Wainwright initiated Q1 2027 earnings estimates for Vivani Medical (NASDAQ:VANI) at a loss of $0.07 per share, maintaining a Buy rating and a $3.50 price target. Despite this, the broader analyst view is more cautious with an average \"Hold\" rating and a $3.75 price target. The", "url": "https://www.marketbeat.com/instant-alerts/analysts-set-expectations-for-vivani-medical-q1-earnings-2026-07-10/", "source_name": "MarketBeat", "published_at": "2026-07-10T12:10:31", "published_display": "10 Jul 2026 12:10", "sentiment": "positive", "sentiment_pct": 61, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Maxim Group Maintains Vivani Medical(VANI.US) With Buy Rating, Maintains Target Price $4", "summary": "Maxim Group has reiterated its Buy rating for Vivani Medical (VANI.US) and maintained its target price at $4. This indicates continued confidence from the firm in the company's performance and future prospects.", "url": "https://www.moomoo.com/news/post/72717105/maxim-group-maintains-vivani-medical-vanius-with-buy-rating-maintains", "source_name": "Moomoo", "published_at": "2026-07-10T10:39:30", "published_display": "10 Jul 2026 10:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Novo Nordisk (CPSE:NOVO B) Could Be 13% Overvalued Following Its Vivani Deal", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/novo-nordisk-cpse-novo-b-161205528.html", "source_name": "Simply Wall St.", "published_at": "2026-07-09T16:12:05+00:00", "published_display": "09 Jul 2026 16:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vivani Medical (VANI) Receives a Buy from Lake Street", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1AFBVV95cUxOM2FPc3czV3VTWmdwak1pc0RDVEQxbWJrUE1TUlU4MEpyQzlLWlJzZFVBd1VMUDJ5ZWJIRVZSaUNTcnBJN2VXbTVZSWRZWjFnX2xCeUtPRGJkaHhlY2ZHTm1zYjRqOW1HNHVtdWZLWU82RzBsS21mcW91b1Eya2tINndHVzJQMFdLeGY3N3BOcFl4WWMzaXFzU21HZGZkODk3VjNkRWticWVwQlVrT3JCZW1TRkwzd3VUZGxDMkQ2YmNVT2R5ZUJtWmNyOW12c2ZkRDV3eA?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-07-08T13:06:00+00:00", "published_display": "08 Jul 2026 13:06", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vivani Advances GLP-1 Implant Program With Novo Nordisk", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2gFBVV95cUxQQjE1cktuQ1Vvcl95cUc5VzZDdGxyamd5Qm5NM0pxUkI5U1MyWjYzWnhaZVpIUUxtT25wQ0ZCU1BvN18zSGZtME5fSE4xYnhod2RFcFExVmw2V1FZYXdRc090eEtKWUp1SWYza3hhaGZQT2xoZmJsbGFQQkxXN2RjWVItTkkxWFpLVE8xQnNzcFNtWWFhY3dpWXJQcmwxSFJpY3VpWFFkR0ZoQUppdFA2UWRKcWRndW1qdVIyTnNUTk85cGl5c3JuQkdjT1VGUjAzNWhOazlpV1AxQQ?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-07-08T12:34:00+00:00", "published_display": "08 Jul 2026 12:34", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Novo Nordisk signs pact with Vivani for long-lasting semaglutide implant", "summary": "", "url": "https://finance.yahoo.com/m/1b4a9ea6-034d-3933-8cbb-34d4e0ca83d5/novo-nordisk-signs-pact-with.html", "source_name": "Pharmaceutical Technology", "published_at": "2026-07-08T11:11:06+00:00", "published_display": "08 Jul 2026 11:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vivani Medical Enters into Agreement with Novo Nordisk to Evaluate NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight Management", "summary": "Vivani Medical has signed an agreement with Novo Nordisk to evaluate NPM-139, Vivani\u2019s ultra long-acting semaglutide implant for chronic weight management. This confirms Novo Nordisk's interest in assessing the NanoPortal\u2122 technology and its semaglutide application. Vivani plans ", "url": "https://www.barchart.com/story/news/3159576/vivani-medical-enters-into-agreement-with-novo-nordisk-to-evaluate-npm-139-a-miniature-ultra-long-acting-semaglutide-implant-for-chronic-weight-management", "source_name": "Barchart.com", "published_at": "2026-07-08T10:39:30", "published_display": "08 Jul 2026 10:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lake Street Maintains Vivani Medical(VANI.US) With Buy Rating, Maintains Target Price $4", "summary": "Lake Street maintained its Buy rating on Vivani Medical (VANI.US) and kept its target price at $4. This indicates continued confidence in the company's prospects from the analyst firm.", "url": "https://www.moomoo.com/news/post/72590558/lake-street-maintains-vivani-medical-vanius-with-buy-rating-maintains", "source_name": "Moomoo", "published_at": "2026-07-07T22:10:31", "published_display": "07 Jul 2026 22:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Novo Nordisk (CPSE:NOVO B) Teams Up With Vivani To Test A Semaglutide Implant", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/novo-nordisk-cpse-novo-b-191804898.html", "source_name": "Simply Wall St.", "published_at": "2026-07-07T19:18:04+00:00", "published_display": "07 Jul 2026 19:18", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vivani Flat on Hookup with Novo", "summary": "Vivani Medical, Inc. announced a new agreement allowing Novo Nordisk to evaluate its semaglutide drug implant, NPM-139, for chronic weight management. Vivani expects to start a Phase 1 study for NPM-139 in mid-2026, comparing it to Wegovy\u00ae injections. This collaboration highlight", "url": "https://www.baystreet.ca/amp/articles/stockstowatch.aspx?articleid=122123", "source_name": "Baystreet.ca", "published_at": "2026-07-07T16:42:11", "published_display": "07 Jul 2026 16:42", "sentiment": "positive", "sentiment_pct": 66, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vivani Medical Says Novo Nordisk to Evaluate Semaglutide Implant for Weight Management", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/vivani-medical-says-novo-nordisk-115918611.html", "source_name": "MT Newswires", "published_at": "2026-07-07T11:59:18+00:00", "published_display": "07 Jul 2026 11:59", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Novo Nordisk will evaluate Vivani\u2019s semaglutide implant for weight loss", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxPSzJYbG5PSkx2M0VlNDA1SG1oQ3ExX3FTRndTUkhXX1g3YTJuQzN2cGZsVjR3TEJLV0VGNk5yZFRZb255RXpTbVF1cmxRd09ET2JaMXBEdHQ1ZElHSE00LUJDUEVJNENMOGFXbkItaTBDZkRtTlBZMG1CYVFvQ2dHZGo1SFNhY1FVQVZGdTAyN0Q0SGd5SWFqQXB6dU5vVjJZbU9sX0tZejdLdE5lSTZ6M1pibGxxOFlPdy1tcDhn?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-07T11:35:00+00:00", "published_display": "07 Jul 2026 11:35", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ClearOne (Nasdaq: CLRO) sets Cortigent merger, Vivani majority stake and $10\u201315M raise", "summary": "ClearOne, Inc. has announced a definitive merger agreement to acquire Cortigent, Inc., a wholly-owned subsidiary of Vivani Medical, Inc. Vivani will receive 12.5 million ClearOne shares, subsequently owning 59.4%\u201367.5% of the combined company, which will be renamed Cortigent Hold", "url": "https://www.stocktitan.net/sec-filings/CLRO/8-k-clearone-inc-reports-material-event-3231d958d02f.html", "source_name": "Stock Titan", "published_at": "2026-07-06T20:31:18", "published_display": "06 Jul 2026 20:31", "sentiment": "positive", "sentiment_pct": 64, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "We're Keeping An Eye On Vivani Medical's (NASDAQ:VANI) Cash Burn Rate", "summary": "Vivani Medical (NASDAQ:VANI) has a critical cash burn situation, with a cash runway of only about 9 months as of March 2026. The company, which is in an early stage without revenue, increased its cash burn by 22% over the last year. Shareholders face potential costly dilution if ", "url": "https://www.sahmcapital.com/news/content/were-keeping-an-eye-on-vivani-medicals-nasdaqvani-cash-burn-rate-2026-07-03", "source_name": "Sahm", "published_at": "2026-07-03T21:09:55", "published_display": "03 Jul 2026 21:09", "sentiment": "negative", "sentiment_pct": 24, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vivani strikes reverse-merger agreement with ClearOne for BCI business", "summary": "Vivani Medical has agreed to merge its neurotech subsidiary, Cortigent, with ClearOne to form a new publicly traded entity, Cortigent Holdings (CRGT), which will focus on brain-computer interface (BCI) technology. Under the agreement, Vivani will hold a majority stake in the new ", "url": "https://finance.yahoo.com/healthcare/articles/vivani-strikes-reverse-merger-agreement-114021364.html", "source_name": "Market source", "published_at": "2026-07-03T11:40:00", "published_display": "03 Jul 2026 11:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Press Release: ClearOne Announces Entry Into Merger Agreement With Cortigent, Inc., a Wholly-Owned Subsidiary of Vivani Medical", "summary": "ClearOne, Inc. has announced a definitive merger agreement with Cortigent, Inc., a wholly-owned subsidiary of Vivani Medical. This strategic transaction will result in Cortigent becoming a public company and is fully supported by Vivani Medical and Cortigent's existing investors.", "url": "https://www.moomoo.com/news/post/72398173/press-release-clearone-announces-entry-into-merger-agreement-with-cortigent", "source_name": "Moomoo", "published_at": "2026-07-02T20:10:13", "published_display": "02 Jul 2026 20:10", "sentiment": "positive", "sentiment_pct": 66, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ClearOne stock surges 50% on Vivani merger deal By Investing.com", "summary": "ClearOne Inc. shares surged over 52% after announcing a merger agreement with Cortigent Inc., a subsidiary of Vivani Medical Inc. Vivani will receive 12.5 million shares of ClearOne common stock, resulting in Vivani owning 59.4% to 67.5% of the combined company, which will be ren", "url": "https://m.za.investing.com/news/stock-market-news/clearone-stock-surges-50-on-vivani-merger-deal-93CH-4354254?ampMode=1", "source_name": "Investing.com South Africa", "published_at": "2026-07-02T15:41:14", "published_display": "02 Jul 2026 15:41", "sentiment": "positive", "sentiment_pct": 72, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vivani to sell neurotech subsidiary Cortigent to ClearOne", "summary": "Vivani Medical announced a definitive agreement to sell its neurotech subsidiary, Cortigent, to ClearOne. The transaction will result in ClearOne being renamed \"Cortigent Holdings, Inc.\" and trading under the Nasdaq ticker \"CRGT,\" with Vivani retaining a majority stake. This move", "url": "https://www.massdevice.com/vivani-sell-neurotech-subsidiary-cortigent-clearone/", "source_name": "MassDevice", "published_at": "2026-07-02T15:41:13", "published_display": "02 Jul 2026 15:41", "sentiment": "positive", "sentiment_pct": 72, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ClearOne Announces Entry into Merger Agreement with Cortigent, Inc., a Wholly-Owned Subsidiary of Vivani Medical", "summary": "ClearOne, Inc. has entered into a definitive merger agreement with Cortigent, Inc., a wholly-owned subsidiary of Vivani Medical. As part of the transaction, Cortigent will become a wholly-owned subsidiary of ClearOne, and ClearOne will conduct a financing round to raise $10 milli", "url": "https://www.businesswire.com/news/home/20260702293602/en/ClearOne-Announces-Entry-into-Merger-Agreement-with-Cortigent-Inc.-a-Wholly-Owned-Subsidiary-of-Vivani-Medical", "source_name": "Business Wire", "published_at": "2026-07-02T11:41:13", "published_display": "02 Jul 2026 11:41", "sentiment": "positive", "sentiment_pct": 66, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vivani Announces Entry into Merger Agreement Between Wholly Owned Subsidiary Cortigent, Inc. and Nasdaq-listed ClearOne, Inc.", "summary": "Vivani Medical, Inc. announced a definitive merger agreement between its wholly-owned subsidiary Cortigent, Inc. and Nasdaq-listed ClearOne", "url": "https://www.globenewswire.com/news-release/2026/07/02/3321264/0/en/vivani-announces-entry-into-merger-agreement-between-wholly-owned-subsidiary-cortigent-inc-and-nasdaq-listed-clearone-inc.html", "source_name": "GlobeNewswire", "published_at": "2026-07-02T11:41:13", "published_display": "02 Jul 2026 11:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Vivani Medical, Inc. \u2013 NASDAQ:VANI", "summary": "This article provides a financial overview of Vivani Medical, Inc. (NASDAQ: VANI), specifically focusing on its forward price-to-earnings ratio. It indicates that the market was closed at the time of the report and there were no trades. The article is primarily a data page from T", "url": "https://www.tradingview.com/symbols/NASDAQ-VANI/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-01T07:39:41", "published_display": "01 Jul 2026 07:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vivani Medical (NASDAQ: VANI) wins HREC nod for SLIM-1 semaglutide implant trial", "summary": "Vivani Medical has received approval from Bellberry, an Australian human research ethics committee, to begin its SLIM-1 Phase 1 clinical trial for NPM-139, a semaglutide implant aimed at obesity and chronic weight management. The trial will assess the safety, tolerability, and ph", "url": "https://www.stocktitan.net/sec-filings/VANI/8-k-vivani-medical-inc-reports-material-event-5764a99801a8.html", "source_name": "Stock Titan", "published_at": "2026-06-30T20:10:12", "published_display": "30 Jun 2026 20:10", "sentiment": "positive", "sentiment_pct": 65, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Vivani Medical Inc. \u2013 DUS:U5P", "summary": "The article focuses solely on the enterprise value to EBIT forward for Vivani Medical Inc. (DUS:U5P). It provides no specific financial figures but presents the topic as a data point for the company listed on the Dusseldorf Stock Exchange. The content is primarily a header and na", "url": "https://www.tradingview.com/symbols/DUS-U5P/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T18:09:43", "published_display": "27 Jun 2026 18:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vivani Medical Announces Appointment of August J. Moretti to Board of Directors and Retirement of Dr. Dean Baker", "summary": "Vivani Medical, Inc. (NASDAQ: VANI) has announced the appointment of August Moretti to its board of directors, where he will chair the Audit Committee and serve on the Compensation Committee. Concurrently, Dr. Dean Baker has retired from the board after a distinguished tenure. Th", "url": "https://www.globenewswire.com/news-release/2026/06/26/3318161/0/en/vivani-medical-announces-appointment-of-august-j-moretti-to-board-of-directors-and-retirement-of-dr-dean-baker.html", "source_name": "GlobeNewswire", "published_at": "2026-06-27T07:09:35", "published_display": "27 Jun 2026 07:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vivani wins approval to start obesity implant trial in Australia", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxNcmwwLXBkLUczMXNCLUtzVVU2NDdiUW5hMDNPQ2NGYlZPZEVSRVo5UVBvTU5pTnRPMDNtazFjb0VfcnZHU1FsSVpQeWFTVWpqZzZRZ0YwZDhtUzBKZzM1bDRPU2VHbUFmb2JJVUphblpCYXM2cEZnUWVMWDFrTXpLNUlPOVdWNG4xYkQxaHI3cS1pWmR6UFR2R2syNGlKaWVCX056VDNPUHU0N1JrVW8tQjk5Znc4MGl5QWx2ZA?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[Form 4] Vivani Medical, Inc. Insider Trading Activity", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxNZHRrdTJnOFhpa3pxc1FVWnBuWG1BZlo1bGt2aHQtUGl4Y2d0SlVna2RKbDRfTFM1dGFlZVhPTXNrNkt6Uk9hX250cGx0b0ZvUXYtdWJIeFQ0dW94T0k5Y0RHMnktckU0a3c0b2pPNXgzTlgyYl9LSnNkOU1iYXVXYm1XajRzRV8wdWlfMkJjNWZ2QWJnbXBIUG0tTzBpR2J4ZXl4LUl5dm9BTUlOQzlzU0dB?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lake Street initiates Vivani Medical stock with buy on implant tech", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxQTEt1aDRVbDlKQ3hlNGcxcHNUYzY3eFFyQlg0cEZ6Y0JkeXVxQTFWR3pjNWtNMWV1XzJWQ3lyQXM0YVRHYlIxUVNMTkxzLWJVMVRoV2FtZ0h2eFlKcjVXNmhnNEpaNUVkQTcyaV82QVBlVEp0QzhzbnpxX3l0VUhpU1NMeVJVYTJYaUswd1RIY1RaakhtZjdNV1UzVjlmZ1QyN0dMcm9zRVUxVWxlV2tXRUYyRThlTDJ4Q2RhZFY3UEJUUEJyc2c?oc=5", "source_name": "Investing.com", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's Why We're Watching Vivani Medical's (NASDAQ:VANI) Cash Burn Situation", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxON0VkRF81QnJWNmpVRjhacHFYSlRpckRFVFlXa0hDTFlLQkx3MHlCY0lwd0tRZmpLaG5hZXVmVXVYMU1xNzIwNDB1VVY5Z2tLaG9hSFdLUXpPNDFMZHREWHgxRzYzV3Z3NUVIbmVxWnFXXy0tRGNGb3c0Z05aRlg3T0o2V2UySy1NVzBRSDdNTHNtZWd4T3prSUQtSQ?oc=5", "source_name": "Market source", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vivani Medical (VANI) Upgraded to Buy: What Does It Mean for the Stock?", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPanplVnRHNFJlZzFCcmRsOGJrb2xUOG1HMkJnUEJFcjExMlRyYmU3Znh6NkctbjZaUVBkeHZvb3Q1dkw0RWlHZWpiRk1CYTl2NWdQcHJZUGVCZkp0UnVzNi1NR0oxSjA0elBULXlSaFF1VjFmQkxSV0Vmcy1tV0xSbVVMdG5EZ3kxYXIteDdMSndpZFNfQ1JkOW8yS2M5dw?oc=5", "source_name": "Market source", "published_at": "2026-04-03T07:00:00+00:00", "published_display": "03 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 84, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Should I buy Vivani Medical, Inc. (VANI)", "summary": "", "url": "https://news.google.com/rss/articles/CBMibEFVX3lxTE1ET1FjWFM3LVFQSmxPTkRJM05FRl9QSmxXbHhFOHZ6czlNVVZSQ3RmMzhtWUVrSVFSQzhGc0FVUW04LWR5QUVLSG5DaEhHVG5oM19meFBQUXZkWTlsYnFsS3YxTmtVYVNFU3ljQw?oc=5", "source_name": "Zacks Investment Research", "published_at": "2026-04-03T07:00:00+00:00", "published_display": "03 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vivani medical director Williams buys shares worth $1.68 million", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxPQzhBUFBPNHRpNWJ2cEdZWEdDbkhwamNXN0RKazZONE1GeFhRMmlRTm1HV3NLS1h2Zmc5TUFzOHNWVk5UUUhPQ1VqWkpBMXpzU3lfekxTREpmbjhPM01JaWdQd0VheU9KTWpCd2lPZ2ZiUGtnaEt4QmlqWlJ4cXRxWXQ5bjBaRDJIQ2pROWlUZUx0Z29KRzZJQlVWR0pRd3VrS091RUo3eTNxeWhxY1ZCTnczQlRFQ3d4Y0JDUkx1eWNfYkR6Zmc?oc=5", "source_name": "Investing.com", "published_at": "2026-03-16T07:00:00+00:00", "published_display": "16 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vivani Medical, Inc. Announces Closing of Common Stock Offering", "summary": "", "url": "https://news.google.com/rss/articles/CBMiigFBVV95cUxOc0NvTFZCcXNxOUZ3MDBKUjExMENMREthcW5DQzl3aDc1blA2Rlp0cnh4QzZHa3VtQ3hjbHZobVVFOXJsaUxRcUhoR3pLQjNXT296VE9XVFdveTB2a3laVDg2V2Jxc3RhbUdzdTRJZWFzM19US1FkaUJ6WndRREFDZWV5Y0JGd3Y3YVE?oc=5", "source_name": "Market source", "published_at": "2026-01-27T08:00:00+00:00", "published_display": "27 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vivani Medical, Inc. (NASDAQ:VANI) insiders have had a fantastic week as stock increased 17%, and they haven't stopped buying", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-23T08:00:00+00:00", "published_display": "23 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insiders hold 43% of Vivani Medical, Inc. (NASDAQ:VANI), and they've been buying recently", "summary": "", "url": "https://news.google.com/rss/articles/CBMigwFBVV95cUxPS0p6V2RIWEpvb2VOUFNEa3dNLXZsTVU2dW13WDllOXpnaUhaajBUWDJyWExBUGx5WFc4SkxKUU9wRlFxWThPdTlKQS1zcHh6SlAtVlQyUzlkTDNvNW9COU9xcDNtbnNzNzNzcUJIQU9IejNWTGdrV1ItSW5PcVJ5OGpDYw?oc=5", "source_name": "Market source", "published_at": "2025-12-05T08:00:00+00:00", "published_display": "05 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vivani Medical (VANI) Stock Price, News & Analysis $VANI", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE5HTnNhN3MydTAxYTVWdzRjWWNRblhNUXNRakpxRVRPSVlSalJUWXVjQlIybkcyMVYwTXUwUEJIcUNFQ3Vzd1BrR09XZDN3VS1pU2ZOUm10ei1oUQ?oc=5", "source_name": "MarketBeat", "published_at": "2022-09-06T12:39:02+00:00", "published_display": "06 Sep 2022 12:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxOWWM3V1pmZzdlY1llRTljQmNLQ2UwdDdQaFVEcng2WVdrNE9qNzRrNVpBVlJNMGltQUhBUG1qellCVHNiM09fUkFHRW1kMEpvazJoLU11N3c4YnlWUXpmVl82aWNKeTA4U1RwSHNNSVd4d0lwWHRJclQ2TGNHWUpBQTgzbTBMVk05VGxYN0RwcmpTYklOQUFSWDhsSHZlQVpndmlPRGNvTmRmeHNILWg4ZE5jMjRoN01XNENiaVU2UDUyOWJfYUZCTm5URmtwTHJsTjJYNHo3RkxsQjBSMnBmdVZVWkFwN2PSAewBQVVfeXFMT3htM016bEt0TTdyOXE2amppMGpubTNfOFU4cGpxd2dFZkJDTjR3c0ZqOHpHYWZoamNLdmkxVmNYNklxTEM4NTU0bDZwUTZ1SW5Jc1c4NmRJN3lKQUVqUUNYYWptd2ZYNE9TeEhMRzFvbEt0bjk1TVhyVG44UnJnNDllTlFsalJVUTZwcEEzWXljbzdaQXdWWDlHQW56bGxqeG90UlFmaFFLekJlUlNIOVE4SGNHcE9pOW1KSllleVdwNERiaVl2NmxtNTNyaUtnSFY1VHUzcDJsWE9xb3R1ajZ2RGhkXzJzTldMOVA?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 97, "total_relevant": 55, "sentiment_summary": {"positive": 22, "negative": 3, "neutral": 30, "score": 58, "total": 55, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 78, "events": [{"event": "general", "label": "Market update", "weight": 15.0, "count": 26}, {"event": "deals", "label": "Deals and strategy", "weight": 4.95, "count": 9}, {"event": "earnings", "label": "Earnings", "weight": 3.85, "count": 9}, {"event": "analyst", "label": "Analyst action", "weight": 3.3, "count": 6}, {"event": "liquidity", "label": "Balance sheet", "weight": 1.1, "count": 2}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 1.1, "count": 2}], "positive_events": 22, "negative_events": 3}, "market_context": {"has_market_context": true, "latest_close": 1.36, "latest_week": "2026-07-10", "one_week_move": 7.9, "four_week_move": 23.6, "twelve_week_move": 1.5, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 0.738785, "market_dynamics_buy_signal": false, "relative_strength": -11.245114, "fair_value_gap": 6.6, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "negative", "expectation_probability": 38.7807, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+7.9% over one week, +23.6% over four weeks, trend inactive, and near fair-value range."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "positive", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 67, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 10}, {"label": "Stock Titan", "count": 6}, {"label": "Investing.com", "count": 4}, {"label": "MarketBeat", "count": 3}, {"label": "GlobeNewswire", "count": 3}, {"label": "Moomoo", "count": 3}, {"label": "TradingView", "count": 3}, {"label": "simplywall.st", "count": 3}], "tiers": [{"label": "Direct company coverage", "count": 47}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 26}, {"label": "Deals and strategy", "count": 9}, {"label": "Earnings", "count": 9}, {"label": "Analyst action", "count": 6}, {"label": "Balance sheet", "count": 2}, {"label": "Regulatory and legal", "count": 2}, {"label": "Guidance", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "58/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "positive", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "78/100 classification confidence."}, {"label": "Company focus", "value": "47", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "2", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+7.9% over one week, +23.6% over four weeks, trend inactive, and near fair-value range."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Vivani Medical Insider Bought Shares Worth $999,999, According to a Recent SEC Filing"}], "updated_at": "2026-07-16T14:29:02.009130+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}